0000000000529304

AUTHOR

Timm Greulich

showing 2 related works from this author

Protocol for the EARCO Registry

2020

Rationale and objectives Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic Obstructive Pulmonary DiseasePopulation1MEDLINElcsh:Medicine61032 Biomedical and Clinical Sciences610 Medicine & health[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciencesLiver diseaseStudy Protocol0302 clinical medicineRare DiseasesClinical ResearchmedicineGenetics030212 general & internal medicineIntensive care medicineeducation3202 Clinical SciencesLungProtocol (science)Emphysemaeducation.field_of_studybusiness.industryPreventionlcsh:Rmedicine.disease3. Good healthNatural historyClinical research030228 respiratory systemObservational study10178 Clinic for PneumologybusinessCohort study
researchProduct

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion

2019

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from th…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyExacerbationAnti-IL-5-therapyCase Report03 medical and health sciences0302 clinical medicineEosinophiliamedicineEosinophiliaIntensive care medicineRespiratory systemInterleukin 5Asthmalcsh:RC705-779business.industryExacerbationlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseasesClinical trial030228 respiratory system030220 oncology & carcinogenesisBreathingmedicine.symptombusinessMepolizumabmedicine.drugRespiratory Medicine Case Reports
researchProduct